Literature DB >> 3755395

1,25-Dihydroxyvitamin D maintains bone cell activity, and parathyroid hormone modulates bone cell number in dogs.

H H Malluche, C Matthews, M C Faugere, P Fanti, D B Endres, R M Friedler.   

Abstract

The singular and combined effects of 1,25-dihydroxyvitamin D [1,25-(OH)2D] and PTH on bone were evaluated in a long term in vivo study in dogs. Dogs were rendered deficient in 1,25-(OH)2D and PTH by five sixths nephrectomy and parathyroidectomy. A control group was sham operated. Various combinations in status of 1,25-(OH)2D and PTH were produced by daily sc injections of 1,25-(OH)2D (1.25) and/or continuous infusion of 1-34 bovine PTH. These were 1.25+/PTH+, 1.25-/PTH-, 1.25+/PTH-, 1.25-/PTH+. Serum calcium levels were kept in the normal range by the administration of one or two of the hormones or by oral supplementation of calcium lactate. Histomorphometric evaluation of static and dynamic parameters of bone after 8 months of experimental observation revealed that deficiency in 1,25-(OH)2D and PTH resulted in decreased number and activity of bone-forming and resorbing cells. Administration of 1,25-(OH)2D increased the activity but not the number of bone cells. In contrast, administration of PTH increased the number but not the activity of bone cells. Tissue level activity was decreased when one or both hormones were deficient, and normal tissue level activity was found only when both hormones were given. These data are relevant for understanding and management of diseases with perturbations in vitamin D and/or PTH.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3755395     DOI: 10.1210/endo-119-3-1298

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  7 in total

1.  Pathogenesis and histology of renal osteodystrophy.

Authors:  H H Malluche; M C Langub; M C Monier-Faugere
Journal:  Osteoporos Int       Date:  1997       Impact factor: 4.507

2.  Vitamin D metabolites prevent vertebral osteopenia in ovariectomized rats.

Authors:  R G Erben; H Weiser; F Sinowatz; W A Rambeck; H Zucker
Journal:  Calcif Tissue Int       Date:  1992-03       Impact factor: 4.333

3.  Increase in femoral bone mass by ipriflavone alone and in combination with 1 alpha-hydroxyvitamin D3 in growing rats with skeletal unloading.

Authors:  K Notoya; K Yoshida; R Tsukuda; S Taketomi; M Tsuda
Journal:  Calcif Tissue Int       Date:  1996-02       Impact factor: 4.333

4.  Calcitriol, parathyroid hormone, and accumulation of aluminum in bone in dogs with renal failure.

Authors:  H H Malluche; M C Faugere; R M Friedler; C Matthews; P Fanti
Journal:  J Clin Invest       Date:  1987-03       Impact factor: 14.808

5.  Dynamic and structural properties of the skeleton in hypoparathyroidism.

Authors:  Mishaela R Rubin; David W Dempster; Hua Zhou; Elizabeth Shane; Thomas Nickolas; James Sliney; Shonni J Silverberg; John P Bilezikian
Journal:  J Bone Miner Res       Date:  2008-12       Impact factor: 6.741

6.  1,25 dihydroxyvitamin D3 alone or in combination with parathyroid hormone does not increase bone mass in young rats.

Authors:  M Gunness-Hey; I Gera; J Fonseca; L G Raisz; J M Hock
Journal:  Calcif Tissue Int       Date:  1988-11       Impact factor: 4.333

7.  A novel synthetic vitamin D analogue, 2 beta-(3-hydroxypropoxy)1 alpha, 25-dihydroxyvitamin D3 (ED-71), increases bone mass by stimulating the bone formation in normal and ovariectomized rats.

Authors:  H Tsurukami; T Nakamura; K Suzuki; K Sato; Y Higuchi; Y Nishii
Journal:  Calcif Tissue Int       Date:  1994-02       Impact factor: 4.333

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.